Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Upstart Holdings Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Upstart Holdings Inc trades at $24.1 (market cap $2.35B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 5.4× Upstart Holdings Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Upstart Holdings Inc for 39 Days on average.
| HALO | UPST | |
|---|---|---|
Market Cap | $12.58B | $2.35B |
Volume | 2,179,278 | 4,203,337 |
Sector | Health | Financials |
52-Week High | $115.22 | $52.74 |
52-Week Low | $61.63 | $22.81 |
Typical Hold Time | 1 Days | 39 Days |
Enterprise Value | $14.49B | $3.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Upstart Holdings (UPST) trades at $24.10, showing modest daily gains but facing technical bearish signals. The company achieved profitability in 2025 with $1.02B revenue and $53.6M net income, though recent quarters show earnings misses. Analyst sentiment is mixed with a $39.50 price target, while technical indicators suggest near-term resistance at $25. Recent news highlights partnership expansions and securitization activity amid sector-wide pressure on consumer lending stocks.
UPST presents a turnaround story with improving fundamentals but faces execution risks in a challenging lending environment. The stock trades below analyst targets offering potential upside, though volatility remains high given recent earnings misses and competitive pressures. Key catalysts include AI lending platform adoption and credit market stability, while risks involve credit quality deterioration and macroeconomic headwinds affecting loan demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
